Coverage
-
July 15, 2011
A Pennsylvania federal judge on Friday approved a settlement between generics maker Teva Pharmaceuticals USA Inc. and Amgen Inc. that squashes Teva's hopes of marketing a copycat version of the blood drug Neopogen until 2013.
1 other articles on this case.
View all »